
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
| Review | Status | Reviewer | Date | Notes |
|---|---|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. | ||
| clinical review | not_started | Awaiting clinician review. | ||
| provenance review | not_started | NPS, FDR Library, and PubMed abstract logged; Bruenn's 1970 article not reviewed in full. | ||
| safe messaging review | not_started | No behavioral-health content; death recorded without graphic detail. |
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|---|---|---|
| 2026-04-10 Progress note 02 (C-CDA) | 12-lead ECG | At initial evaluation; repeat with symptom change, arrhythmia, or device consideration | No ECG from the diagnostic workup is on file, a deviation from the protocol. Rhythm is regular on examination and no device decision is due yet, so no harm has resulted. Corrective action: obtain an ECG before the device decision that follows the repeat echocardiogram |
| 2026-04-10 Progress note 02 (C-CDA) | Liver tests (initial workup; ALT before starting a statin) | Once at diagnosis | No liver panel from the diagnostic visit is on file, a deviation from the heart failure and lipid protocols. He has no symptoms of liver injury. Routine liver monitoring on a statin is not recommended, so the corrective action is to test ALT only if symptoms appear |
| 2026-06-26 Progress note 03 (C-CDA) | Basic metabolic panel 1 to 2 weeks after the April changes | Once, after titrating sacubitril/valsartan and starting spironolactone | Not drawn in the window: the panel planned for the second iron infusion was not done, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted. Corrective action: each medication change now comes with a dated laboratory appointment booked before he leaves |
| 2026-06-26 Progress note 03 (C-CDA) | Lipid panel | 4 to 12 weeks after starting a statin | Not drawn in the window, which closed last week, and not on today's order, a deviation from the lipid protocol. He takes every dose and has no muscle symptoms, and a three-month delay in confirming the response carries little risk. Corrective action: added to the six-month laboratory order |
| 2026-09-25 Progress note 05 (C-CDA) | Basic metabolic panel after stopping furosemide in June | 1 to 2 weeks after a diuretic change | Not drawn in the window, a deviation from the protocol. The next panel was at the July sick visit, about four and a half weeks later, with potassium 4.9 during volume depletion; today's potassium is 4.5, so no harm resulted. This is the second missed post-change check this year; the corrective action is the dated laboratory appointment at every medication change |
| 2026-09-25 Progress note 05 (C-CDA) | Basic metabolic panel after restarting the medicines held in July | 1 to 2 weeks after restarting sacubitril/valsartan, spironolactone, and empagliflozin | The sick-visit plan moved the recheck to today; strictly, the protocol calls for a panel within two weeks of a restart, so this is recorded as a deviation. Today's potassium and creatinine are at baseline, so no harm resulted. Corrective action: a panel one to two weeks after any future sick-day restart |
| 2026-09-25 Progress note 05 (C-CDA) | Magnesium | With each basic metabolic panel | Not measured with any panel since diagnosis, a deviation from the protocol. He has had no arrhythmia or cramps and has been off the loop diuretic since June, so the risk of low magnesium is small. Corrective action: added to the three-month panel |
| 2026-09-25 Progress note 05 (C-CDA) | 12-lead ECG | At initial evaluation; repeat with device consideration | Still not on file, a deviation carried from April. No device decision is needed now that the ejection fraction is 45 percent, and his rhythm is regular, so no harm has resulted. Corrective action: ECG at the three-month review |
| Visit | Type | Item | Status | Detail |
|---|---|---|---|---|
| 2026-06-26 Progress note 03 (C-CDA) | Referral | Cardiac rehabilitation | Referred | Eligible: ejection fraction 30 percent, NYHA II, three months of therapy, no hospital stay. Referred to a program that adapts training for wheelchair users with arm ergometry and resistance bands |
| 2026-10-23 Progress note 06 (C-CDA) | Prevention | Lung cancer screening | Ordered | More than 30 pack-years and quit six months ago. After shared decision-making about benefits, false positives, and radiation, he chose annual low-dose CT; first scan ordered |
| 2026-10-23 Progress note 06 (C-CDA) | Prevention | Colorectal cancer screening | Ordered | No prior screening on record. Options discussed; because bowel preparation and the toileting it requires are hard for him, he chose a yearly fecal immunochemical test, and a kit was given today. A positive test needs colonoscopy |
| 2026-10-23 Progress note 06 (C-CDA) | Prevention | Hepatitis C and HIV screening | Ordered | One-time screening recommended for all adults in these age ranges; no prior result on record; added to the next blood draw |
| Claim | Statement | Certainty |
|---|---|---|
| CLM-0004 | A 2003 Bayesian analysis of the recorded symptoms concluded that Guillain-Barré syndrome was more probable than paralytic polio as the cause of Roosevelt's 1921 illness; the conclusion is disputed and cannot be confirmed because no cerebrospinal fluid was examined. | disputed |
None.
| Problem | Code | Verification | Reason |
|---|---|---|---|
| Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed | B91 | provisional | Synthetic modern coding of the documented diagnosis; the alternative cause remains R. |
Every note in the record, with its type. All clinical content is synthetic.
| Date | Result | Value | Flag |
|---|---|---|---|
| 2026-03-27 | NT-proBNP | 2850 pg/mL (high) | High |
| 2026-03-27 | Glucose | 104 mg/dL (high) | High |
| 2026-03-27 | Hemoglobin | 12.6 g/dL (low) | Low |
| 2026-03-27 | Transferrin saturation | 16% (low) | Low |
| 2026-03-27 | LDL cholesterol | 132 mg/dL (high) | High |
| 2026-03-27 | HbA1c | 5.9% (high) | High |
| 2026-03-27 | Urine albumin-creatinine ratio | 64 mg/g (high) | High |
| 2026-04-10 | LVEF by echocardiogram | 30% (low) | Low |
| 2026-06-26 | NT-proBNP | 980 pg/mL (high) | High |
| 2026-09-25 | NT-proBNP | 410 pg/mL (high) | High |
| 2026-09-25 | LVEF by echocardiogram | 45% (low) | Low |
| 2026-07-27 | Creatinine | 1.42 mg/dL (high) | High |
| 2026-07-27 | eGFR | 56 mL/min/1.73 m² (low) | Low |